Checkmate Pharmaceuticals is a cancer R&D driven startup developing cancer immunotherapy by utilizing immune checkpoint proteins inhibitors combined with an immune activator to stimulate the CTL attack against the tumor.
Checkmates founder and CEO, Dr. Art Krieg, discovered CpG DNA in 1994. CpG DNA (Toll-like receptor 9 agonist) has been found as the strongest at activating anti-tumor CTLs response.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Checkmate is validating an approach that will combine the ability of CpG DNA to activate an anti-tumor T cell response along with checkpoint inhibition to overcome a tumors ability to mute the immune response.
In Aug 2015, Checkmate acquired licence of clinically validated virus-like particle (VLP) platform and clinical product (CYT003) along with technologies related to oligonucleotide synthesis & VLP delivery from Cytos Biotechnology, for its use in oncology.
In Aug 2015, Checkmate Pharmaceuticals received $20 Mn series A financing from Sofinnova Ventures and venBio.
Recover your password.
A password will be e-mailed to you.